Zenas BioPharma, Inc. Common Stock (ZBIO) - Total Liabilities
Based on the latest financial reports, Zenas BioPharma, Inc. Common Stock (ZBIO) has total liabilities worth $411.85 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Zenas BioPharma, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Zenas BioPharma, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Zenas BioPharma, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Zenas BioPharma, Inc. Common Stock to measure how efficiently the company converts operating cash flow to free cash.
Zenas BioPharma, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Zenas BioPharma, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ta Liang Technology Co Ltd
TW:3167
|
Taiwan | NT$6.83 Billion |
|
Guangdong Advertising Co Ltd
SHE:002400
|
China | CN¥7.50 Billion |
|
Pharvaris BV
NASDAQ:PHVS
|
USA | $26.66 Million |
|
Tibet Mineral Development Co Ltd
SHE:000762
|
China | CN¥3.59 Billion |
|
Mercuries Life Insurance Co Ltd
TW:2867
|
Taiwan | NT$1.49 Trillion |
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
China | CN¥1.56 Billion |
|
BitVentures Limited
NASDAQ:BVC
|
USA | $11.07 Million |
|
Isrotel -L
TA:ISRO
|
Israel | ILA2.62 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Zenas BioPharma, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zenas BioPharma, Inc. Common Stock stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zenas BioPharma, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zenas BioPharma, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Zenas BioPharma, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $141.50 Million | +146.04% |
| 2024-12-31 | $57.51 Million | -80.43% |
| 2023-12-31 | $293.90 Million | +10.13% |
| 2022-12-31 | $266.87 Million | -- |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more